secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2026-09-11T11:00:21+00:00
Accession:  0000939767-26-000108
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA extends review of Exelixis' zanzalintinib+atezolizumab NDA for mCRC by 3 months
--------------------------------------------------------------------------------

- FDA deemed submitted safety/efficacy data a major amendment; PDUFA date extended to March 3, 2027.
- Extension triggered by Exelixis' response to FDA information request for the metastatic colorectal cancer NDA.
- Zanzalintinib combined with atezolizumab is under review for patients with metastatic colorectal cancer.
- No change to existing approved products; delay adds 3 months to regulatory decision timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976726000108/0000939767-26-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976726000108/exel-20260910.htm
  HTML page:      https://secwatch.observer/filing/0000939767-26-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer